sorafenib has been researched along with Bilirubinemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, SH; Cheong, JY; Han, SY; Hwang, J; Kim, BH; Kim, DY; Kim, HY; Kim, YJ; Kwon, OS; Lee, HC; Lee, YJ; Paik, SW; Park, JW; Yeon, JE | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R | 1 |
| Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R | 1 |
1 trial(s) available for sorafenib and Bilirubinemia
| Article | Year |
|---|---|
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperbilirubinemia; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Thrombocytopenia | 2019 |
3 other study(ies) available for sorafenib and Bilirubinemia
| Article | Year |
|---|---|
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Cyclophosphamide; Doxorubicin; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Sorafenib | 2009 |
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |